Russell Smith

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Imperial Chemical Industries Ltd. manufactures chemicals and paint products. Its products include coatings, adhesives, starch, and synthetic polymer. The company was founded on December 7, 1926 and is headquartered in Slough, the United Kingdom.

Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK.

Axellis, Inc. sells and distributes medical devices. Its products are used for oncology and cardiology. The company was founded in August 2007 and is headquartered in London, UK

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Part of Commerzbank AG, Commerzbank Finance Ltd. is a British company that provides securities brokerage services. The company is based in London, UK. Commerzbank Finance was founded in 1955.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.

Oxfordshire Biotechnet Ltd. is a venture capital fund.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Biotecnol-Serviços e Desenvolvimento SA engages in the discovery, engineering, and development of multifunctional antibody molecules, directed to key therapeutic targets. The firm operates as a biopharmaceutical company working in the field of immuno-oncology. It uses Tribody technology to develop a pipeline of in-house discovered products in selected oncology indications. The company was founded in 1997 and is headquartered in Oeiras, Portugal.

Northland Capital Partners Ltd. provides investment banking services. The private company is based in London, UK. and has subsidiaries in United Kingdom. The British company was founded in 1991. Robert Alan Johnson has been the CEO of the company since 2010.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Biotecnol Ltd. engages in research & development of immuno-oncology antibody products. It specializes in recombinant antibodies, T cell engaging, multispecific antibodies and oncology. The company is headquartered in London, the United Kingdom.

Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom.

Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.

Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom.

Trimunocor Ltd. is a private company based in Harpenden, UK that focuses on developing ground-breaking solutions to protect premature neonates from chronic lung disease. Trimunocor is a spin-out based on IP from the Medical Research Council and University of Southampton. The British company's website provides information about their solution and their focus, as well as news and events. Visitors can also subscribe to stay up to date with the latest developments. The company was founded by Neill Moray MacKenzie and Howard Clark, with Neill Moray MacKenzie serving as CEO since incorporation.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

Our Future Health UK is a collaboration between the public, private, and charity sectors. Our Future Health UK is a member of the UK Health Data Research Alliance, which establishes best practices for the ethical use of UK health data for research at scale. The private company is based in Manchester, UK. The British company aims to be the largest health research program in the UK, bringing people together to develop new ways to prevent, detect, and treat diseases. The company is committed to protecting participants' confidentiality while maximizing the opportunity to help researchers tackle serious diseases. The CEO of the company is Andrew Roddam.

Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023.

Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors.

Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue.